Hyundai Bioscience Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 43.36 million compared to KRW 30.29 million a year ago. Net loss was KRW 2,096.82 million compared to KRW 2,134.43 million a year ago.

Basic loss per share from continuing operations was KRW 53 compared to KRW 55 a year ago. Diluted loss per share from continuing operations was KRW 53 compared to KRW 55 a year ago. Basic loss per share was KRW 53 compared to KRW 55 a year ago.